194 related articles for article (PubMed ID: 11497249)
1. uPA and uPAR contribute to NK cell invasion through the extracellular matrix.
Al-Atrash G; Kitson RP; Xue Y; Mazar AP; Kim MH; Goldfarb RH
Anticancer Res; 2001; 21(3B):1697-704. PubMed ID: 11497249
[TBL] [Abstract][Full Text] [Related]
2. Cooperation of urokinase plasminogen activator and matrix metalloproteinases in NK cell invasion.
al-Atrash G; Kitson RP; Xue Y; Goldfarb RH
In Vivo; 2000; 14(5):565-70. PubMed ID: 11125540
[TBL] [Abstract][Full Text] [Related]
3. Physical association of uPAR with the alphaV integrin on the surface of human NK cells.
Gellert GC; Goldfarb RH; Kitson RP
Biochem Biophys Res Commun; 2004 Mar; 315(4):1025-32. PubMed ID: 14985115
[TBL] [Abstract][Full Text] [Related]
4. Calcitonin inhibits invasion of breast cancer cells: involvement of urokinase-type plasminogen activator (uPA) and uPA receptor.
Han B; Nakamura M; Zhou G; Ishii A; Nakamura A; Bai Y; Mori I; Kakudo K
Int J Oncol; 2006 Apr; 28(4):807-14. PubMed ID: 16525628
[TBL] [Abstract][Full Text] [Related]
5. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice.
Bauer TW; Liu W; Fan F; Camp ER; Yang A; Somcio RJ; Bucana CD; Callahan J; Parry GC; Evans DB; Boyd DD; Mazar AP; Ellis LM
Cancer Res; 2005 Sep; 65(17):7775-81. PubMed ID: 16140945
[TBL] [Abstract][Full Text] [Related]
6. The effects of cyclooxygenase2-prostaglandinE2 pathway on Helicobacter pylori-induced urokinase-type plasminogen activator system in the gastric cancer cells.
Iwamoto J; Mizokami Y; Takahashi K; Matsuoka T; Matsuzaki Y
Helicobacter; 2008 Jun; 13(3):174-82. PubMed ID: 18466392
[TBL] [Abstract][Full Text] [Related]
7. The urokinase plasminogen activator (uPA) system in uterine natural killer cells in the placental bed during early pregnancy.
Naruse K; Lash GE; Bulmer JN; Innes BA; Otun HA; Searle RF; Robson SC
Placenta; 2009 May; 30(5):398-404. PubMed ID: 19272641
[TBL] [Abstract][Full Text] [Related]
8. Binding of urokinase to its receptor promotes migration and invasion of human melanoma cells in vitro.
Stahl A; Mueller BM
Cancer Res; 1994 Jun; 54(11):3066-71. PubMed ID: 8187097
[TBL] [Abstract][Full Text] [Related]
9. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
10. Modulation of invasive properties of human glioblastoma cells stably expressing amino-terminal fragment of urokinase-type plasminogen activator.
Mohanam S; Chandrasekar N; Yanamandra N; Khawar S; Mirza F; Dinh DH; Olivero WC; Rao JS
Oncogene; 2002 Nov; 21(51):7824-30. PubMed ID: 12420219
[TBL] [Abstract][Full Text] [Related]
11. DU145 human prostate carcinoma invasiveness is modulated by urokinase receptor (uPAR) downstream of epidermal growth factor receptor (EGFR) signaling.
Mamoune A; Kassis J; Kharait S; Kloeker S; Manos E; Jones DA; Wells A
Exp Cell Res; 2004 Sep; 299(1):91-100. PubMed ID: 15302576
[TBL] [Abstract][Full Text] [Related]
12. Macrophage colony-stimulating factor mediates invasion of ovarian cancer cells through urokinase.
Chambers SK; Wang Y; Gertz RE; Kacinski BM
Cancer Res; 1995 Apr; 55(7):1578-85. PubMed ID: 7882368
[TBL] [Abstract][Full Text] [Related]
13. Role of urokinase plasminogen activator receptor in thrombospondin 1-mediated tumor cell invasion.
Albo D; Berger DH; Rothman VL; Tuszynski GP
J Surg Res; 1999 Apr; 82(2):331-8. PubMed ID: 10090848
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of urokinase receptor increases matrix invasion without altering cell migration in a human osteosarcoma cell line.
Karikó K; Kuo A; Boyd D; Okada SS; Cines DB; Barnathan ES
Cancer Res; 1993 Jul; 53(13):3109-17. PubMed ID: 8391387
[TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor modulates prostate cancer cell invasiveness regulating urokinase-type plasminogen activator activity. EGF-receptor inhibition may prevent tumor cell dissemination.
Festuccia C; Angelucci A; Gravina GL; Biordi L; Millimaggi D; Muzi P; Vicentini C; Bologna M
Thromb Haemost; 2005 May; 93(5):964-75. PubMed ID: 15886816
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-1alpha enhances the aggressive behavior of pancreatic cancer cells by regulating the alpha6beta1-integrin and urokinase plasminogen activator receptor expression.
Sawai H; Okada Y; Funahashi H; Matsuo Y; Takahashi H; Takeyama H; Manabe T
BMC Cell Biol; 2006 Feb; 7():8. PubMed ID: 16504015
[TBL] [Abstract][Full Text] [Related]
17. Murine monoclonal antibodies against murine uPA receptor produced in gene-deficient mice: inhibitory effects on receptor-mediated uPA activity in vitro and in vivo.
Pass J; Jögi A; Lund IK; Rønø B; Rasch MG; Gårdsvoll H; Lund LR; Ploug M; Rømer J; Danø K; Høyer-Hansen G
Thromb Haemost; 2007 Jun; 97(6):1013-22. PubMed ID: 17549305
[TBL] [Abstract][Full Text] [Related]
18. Urokinase plasminogen activator, uPa receptor, and its inhibitor in vernal keratoconjunctivitis.
Leonardi A; Brun P; Sartori MT; Cortivo R; Dedominicis C; Saggiorato G; Abatangelo G; Secchi AG
Invest Ophthalmol Vis Sci; 2005 Apr; 46(4):1364-70. PubMed ID: 15790903
[TBL] [Abstract][Full Text] [Related]
19. Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).
Magdolen V; Bürgle M; de Prada NA; Schmiedeberg N; Riemer C; Schroeck F; Kellermann J; Degitz K; Wilhelm OG; Schmitt M; Kessler H
Biol Chem; 2001 Aug; 382(8):1197-205. PubMed ID: 11592401
[TBL] [Abstract][Full Text] [Related]
20. Modulation of in vitro invasion of human glioblastoma cells by urokinase-type plasminogen activator receptor antibody.
Mohanam S; Sawaya R; McCutcheon I; Ali-Osman F; Boyd D; Rao JS
Cancer Res; 1993 Sep; 53(18):4143-7. PubMed ID: 8395977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]